Veto Cell‑augmented Allogeneic HSCT
Hematologic malignancies and non‑malignant disorders
Phase 1/2Active
Key Facts
Indication
Hematologic malignancies and non‑malignant disorders
Phase
Phase 1/2
Status
Active
Company
About Cell Source
Innovative Veto Cell platform enabling donor‑free transplants and durable CAR‑T cancer therapies.
View full company profile